JP2005523281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523281A5 JP2005523281A5 JP2003569193A JP2003569193A JP2005523281A5 JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5 JP 2003569193 A JP2003569193 A JP 2003569193A JP 2003569193 A JP2003569193 A JP 2003569193A JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- alpha
- pharmaceutically acceptable
- delta ligand
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010007710 Cartilage injury Diseases 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- -1 1-aminomethyl-cyclohexylmethyl Chemical group 0.000 claims 1
- UVUQVKDHNYUOJX-UHFFFAOYSA-N 2h-oxadiazol-5-one;hydrochloride Chemical compound Cl.O=C1C=NNO1 UVUQVKDHNYUOJX-UHFFFAOYSA-N 0.000 claims 1
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
Claims (10)
- アルファ−2−デルタリガンドがガバペンチンである、請求項1に記載の組合せ。
- アルファ−2−デルタリガンドがプレガバリンである、請求項1に記載の組合せ。
- アルファ−2−デルタリガンドが、3−(1−アミノメチル−シクロヘキシルメチル)−4H−[1,2,4]オキサジアゾール−5−オン塩酸塩と称する化合物である、請求項1に記載の組合せ。
- アルファ−2−デルタリガンドが、(3S,4S)−(1−アミノメチル−3,4−ジメチル−シクロペンチル)−酢酸と称する化合物、またはその医薬上許容しうる塩である、請求項1に記載の組合せ。
- 請求項1に記載の組合せおよび医薬上許容しうる担体、希釈剤または賦形剤を含む医薬組成物。
- 請求項2〜5のいずれか1項に記載の組合せおよび医薬上許容しうる担体、希釈剤または賦形剤を含んでなる、請求項6に記載の医薬組成物。
- 哺乳動物における軟骨損傷、炎症、変形性関節症、慢性関節リウマチ、乾癬性関節炎、または疼痛の治療に有効な医薬の製造における請求項1に記載の組合せの使用。
- 組合せが請求項2〜5のいずれか1項による、請求項8に記載の使用。
- 請求項1〜5のいずれか1項に記載の組合せを含有する、軟骨損傷、炎症、変形性関節症、慢性関節リウマチ、乾癬性関節炎または疼痛の治療用医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35929502P | 2002-02-22 | 2002-02-22 | |
US40436502P | 2002-08-19 | 2002-08-19 | |
PCT/IB2003/000534 WO2003070237A1 (en) | 2002-02-22 | 2003-02-12 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005523281A JP2005523281A (ja) | 2005-08-04 |
JP2005523281A5 true JP2005523281A5 (ja) | 2006-03-30 |
Family
ID=27760521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003569193A Abandoned JP2005523281A (ja) | 2002-02-22 | 2003-02-12 | アルファ−2−デルタリガンドとシクロオキシゲナーゼ−2の選択的阻害剤との組合せ |
Country Status (21)
Country | Link |
---|---|
US (1) | US20030199567A1 (ja) |
EP (1) | EP1480639A1 (ja) |
JP (1) | JP2005523281A (ja) |
KR (1) | KR20040085216A (ja) |
CN (1) | CN1635887A (ja) |
AR (1) | AR038531A1 (ja) |
AU (1) | AU2003246864A1 (ja) |
BR (1) | BR0307906A (ja) |
CA (1) | CA2476438A1 (ja) |
CO (1) | CO5611109A2 (ja) |
HN (1) | HN2003000071A (ja) |
IL (1) | IL162932A0 (ja) |
MX (1) | MXPA04008175A (ja) |
NO (1) | NO20043947L (ja) |
PA (1) | PA8567201A1 (ja) |
PE (1) | PE20031052A1 (ja) |
PL (1) | PL372210A1 (ja) |
RU (1) | RU2286151C2 (ja) |
TW (1) | TW200303214A (ja) |
UY (1) | UY27675A1 (ja) |
WO (1) | WO2003070237A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2509605C (en) * | 2002-12-13 | 2010-10-05 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
CN1791399A (zh) * | 2003-03-21 | 2006-06-21 | 戴诺根医药品公司 | 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法 |
WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
WO2004084880A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
MXPA06002789A (es) * | 2003-09-12 | 2006-06-14 | Pfizer | Combinaciones que comprenden ligandos alfa-2-delta. |
GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
WO2005041976A2 (en) * | 2003-10-23 | 2005-05-12 | Medtronic, Inc. | Injectable gabapentin compositions |
US7888351B2 (en) * | 2006-04-11 | 2011-02-15 | Novartis Ag | Organic compounds |
JP2010513357A (ja) * | 2006-12-22 | 2010-04-30 | ノバルティス アーゲー | Dpp−iv阻害剤としての1−アミノメチル−1−フェニル−シクロヘキサン誘導体 |
CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
KR101851120B1 (ko) * | 2008-09-05 | 2018-04-23 | 그뤼넨탈 게엠베하 | 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물 |
KR102631399B1 (ko) | 2018-03-30 | 2024-02-01 | 씨지인바이츠 주식회사 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
JP2023548380A (ja) * | 2020-10-28 | 2023-11-16 | トレモー・ファーマシューティカルズ・インコーポレイテッド | 非水溶性cox-2阻害の水性製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5352638A (en) * | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
DE69832712T2 (de) * | 1997-09-08 | 2006-06-22 | Warner-Lambert Company Llc | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen |
JP2002508352A (ja) * | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | 4(3)置換−4(3)−アミノメチル−(チオ)ピラン又はピペリジン誘導体(=ガバペンチン類似体)、それらの製法および神経病理学的疾患の治療における使用 |
AU3216600A (en) * | 1999-03-10 | 2000-09-28 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
-
2003
- 2003-02-12 IL IL16293203A patent/IL162932A0/xx unknown
- 2003-02-12 CN CNA038043564A patent/CN1635887A/zh active Pending
- 2003-02-12 WO PCT/IB2003/000534 patent/WO2003070237A1/en not_active Application Discontinuation
- 2003-02-12 CA CA002476438A patent/CA2476438A1/en not_active Abandoned
- 2003-02-12 EP EP03742460A patent/EP1480639A1/en not_active Withdrawn
- 2003-02-12 RU RU2004125609/15A patent/RU2286151C2/ru not_active IP Right Cessation
- 2003-02-12 AU AU2003246864A patent/AU2003246864A1/en not_active Abandoned
- 2003-02-12 BR BR0307906-6A patent/BR0307906A/pt not_active IP Right Cessation
- 2003-02-12 JP JP2003569193A patent/JP2005523281A/ja not_active Abandoned
- 2003-02-12 PL PL03372210A patent/PL372210A1/xx not_active Application Discontinuation
- 2003-02-12 MX MXPA04008175A patent/MXPA04008175A/es unknown
- 2003-02-12 KR KR10-2004-7013032A patent/KR20040085216A/ko not_active Application Discontinuation
- 2003-02-14 US US10/366,798 patent/US20030199567A1/en not_active Abandoned
- 2003-02-17 PE PE2003000166A patent/PE20031052A1/es not_active Application Discontinuation
- 2003-02-19 UY UY27675A patent/UY27675A1/es not_active Application Discontinuation
- 2003-02-20 AR ARP030100547A patent/AR038531A1/es unknown
- 2003-02-21 TW TW092103596A patent/TW200303214A/zh unknown
- 2003-02-21 HN HN2003000071A patent/HN2003000071A/es unknown
- 2003-02-21 PA PA20038567201A patent/PA8567201A1/es unknown
-
2004
- 2004-08-13 CO CO04079024A patent/CO5611109A2/es not_active Application Discontinuation
- 2004-09-21 NO NO20043947A patent/NO20043947L/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005523281A5 (ja) | ||
RU2379295C2 (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
JP2005523922A5 (ja) | ||
RU2333205C2 (ru) | Производные бензотиадиазепина, способ их получения и их применение, фармацевтическая композиция, обладающая ингибирующей активностью в отношении переноса желчных кислот в подвздошной кишке | |
RU2011129222A (ru) | Гемифумаратная соль 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил] азетидин-3-карбоновой кислоты | |
EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
JP2007534702A5 (ja) | ||
JP2008543854A5 (ja) | ||
RU2004125609A (ru) | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 | |
RU2009106934A (ru) | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента | |
WO2006098918B1 (en) | Substituted gamma lactams as therapeutic agents | |
JP2009504763A5 (ja) | ||
RU2010145459A (ru) | Ингибиторы активности протеинтирозинкиназы | |
EA200870384A1 (ru) | 3,7-диамино-10h-фенотиазиновые соли и их применение | |
JP2009525302A5 (ja) | ||
CA2158352A1 (en) | Hydroxamic acid derivatives as metalloproteinase inhibitors | |
JP2004517813A5 (ja) | ||
RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
JP2013502461A5 (ja) | ||
RU2006131043A (ru) | Соединения силинана в качестве ингибиторов цистеиновой протеазы | |
CA2281426A1 (en) | Substituted indole compounds as anti-inflammatory and analgesic agents | |
JP2008542386A5 (ja) | ||
JP2008534534A5 (ja) | ||
KR20070091049A (ko) | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 | |
RU2003134629A (ru) | Соединения цефема |